A Multi-center, Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of PHP-201 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Latest Information Update: 07 Nov 2023
At a glance
- Drugs PHP 201 (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors pH Pharma
- 13 Jun 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last Verified April 2021).
- 13 Jun 2021 Planned End Date changed from 1 Nov 2025 to 1 Nov 2023.
- 04 May 2021 New trial record